Short Interest in Evaxion Biotech A/S (NASDAQ:EVAX) Drops By 21.1%

Evaxion Biotech A/S (NASDAQ:EVAX) was the target of a significant decline in short interest in October. As of October 15th, there was short interest totalling 67,400 shares, a decline of 21.1% from the September 30th total of 85,400 shares. Based on an average daily volume of 48,700 shares, the days-to-cover ratio is currently 1.4 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $14.00 price objective on shares of Evaxion Biotech A/S in a research report on Thursday, September 26th.

Hedge Funds Weigh In On Evaxion Biotech A/S

A hedge fund recently bought a new stake in Evaxion Biotech A/S stock. Invst LLC acquired a new stake in Evaxion Biotech A/S (NASDAQ:EVAX) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 54,000 shares of the company’s stock, valued at approximately $156,000. Invst LLC owned about 1.00% of Evaxion Biotech A/S at the end of the most recent reporting period. Institutional investors and hedge funds own 11.04% of the company’s stock.

Evaxion Biotech A/S Stock Performance

NASDAQ EVAX traded up $0.08 on Monday, hitting $2.84. 14,097 shares of the stock were exchanged, compared to its average volume of 233,771. The company has a debt-to-equity ratio of 7.99, a current ratio of 2.80 and a quick ratio of 2.80. The business’s fifty day moving average is $3.00 and its 200 day moving average is $3.23. Evaxion Biotech A/S has a 52 week low of $2.26 and a 52 week high of $13.61. The company has a market capitalization of $15.85 million, a PE ratio of -1.17 and a beta of -0.26.

Evaxion Biotech A/S (NASDAQ:EVAX) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.14). The business had revenue of $0.15 million for the quarter, compared to analysts’ expectations of $0.10 million. During the same quarter in the prior year, the business earned ($2.10) earnings per share. Research analysts anticipate that Evaxion Biotech A/S will post -0.24 EPS for the current fiscal year.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.